TG Therapeutics, Inc. SEC filings TGTX
TG Therapeutics, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Feb 28, 2003. Its latest annual report, Form 10-K, was filed on Feb 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 3, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 11, 2026 |
| DEFA14A | Additional proxy material | Apr 30, 2025 | — |
| DEF 14A | Proxy statement | Apr 30, 2025 | Jun 12, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2025 | Jun 12, 2025 |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 14, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 18, 2024 | Jun 4, 2024 |
| DEFA14A | Additional proxy material | May 1, 2023 | — |
| DEF 14A | Proxy statement | May 1, 2023 | — |
| PRE 14A | Preliminary proxy statement | Apr 21, 2023 | — |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 16, 2022 |
| DEFA14A | Additional proxy material | Apr 30, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 16, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2021 | Jun 16, 2021 |
| DEFA14A | Additional proxy material | Apr 29, 2020 | — |
| DEF 14A | Proxy statement | Apr 29, 2020 | Jun 18, 2020 |
| DEFA14A | Additional proxy material | Apr 30, 2019 | — |
| DEF 14A | Proxy statement | Apr 30, 2019 | Jun 13, 2019 |
| DEFA14A | Additional proxy material | Apr 30, 2018 | — |
| DEF 14A | Proxy statement | Apr 30, 2018 | Jun 13, 2018 |
| DEF 14A | Proxy statement | Apr 28, 2017 | Jun 16, 2017 |
| DEF 14A | Proxy statement | Apr 29, 2016 | Jun 14, 2016 |
| DEF 14A | Proxy statement | Apr 24, 2015 | Jun 4, 2015 |
| DEF 14A | Proxy statement | Apr 23, 2014 | Jun 6, 2014 |
| PRE 14A | Preliminary proxy statement | Apr 11, 2014 | Jun 6, 2014 |
| DEF 14A | Proxy statement | Apr 24, 2013 | Jun 5, 2013 |
| DEF 14A | Proxy statement | Mar 15, 2012 | Apr 16, 2012 |
| PRE 14A | Preliminary proxy statement | Mar 5, 2012 | Mar 5, 2012 |
| DEF 14A | Proxy statement | Mar 22, 2011 | May 20, 2011 |
| PRE 14A | Preliminary proxy statement | Mar 1, 2011 | May 13, 2011 |
| DEF 14A | Proxy statement | Oct 29, 2009 | Nov 30, 2009 |
| PRE 14A | Preliminary proxy statement | Sep 29, 2009 | Nov 16, 2009 |
| DEF 14A | Proxy statement | May 12, 2008 | Jun 26, 2008 |
| PRE 14A | Preliminary proxy statement | Apr 25, 2008 | Apr 25, 2008 |
| DEF 14A | Proxy statement | Apr 30, 2007 | May 24, 2007 |
| DEF 14A | Proxy statement | Nov 17, 2006 | Dec 15, 2006 |
| DEF 14A | Proxy statement | Oct 21, 2005 | Nov 18, 2005 |
| DEF 14A | Proxy statement | Jul 28, 2004 | Aug 20, 2004 |
| PRE 14A | Preliminary proxy statement | Jul 27, 2004 | Jul 26, 2004 |
| DEF 14C | Information statement | Aug 28, 2003 | Aug 28, 2003 |
| PRE 14C | Preliminary information statement | Aug 15, 2003 | Aug 15, 2003 |
| DEF 14C | Information statement | Jun 20, 2003 | Jun 20, 2003 |
| PRE 14C | Filing | May 28, 2003 | May 28, 2003 |
Showing 44 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TGTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1001316
- Former names
- MANHATTAN PHARMACEUTICALS INC (until Apr 27, 2012); ATLANTIC TECHNOLOGY VENTURES INC (until Mar 10, 2003); ATLANTIC PHARMACEUTICALS INC (until Feb 4, 2000)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.